Clene Inc. (NASDAQ: CLNN), a biopharmaceutical company, is making significant strides in transforming the treatment of neurodegenerative disorders, particularly amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). The company's lead agent, CNM-Au8, focuses on the nicotinamide adenine dinucleotide (NAD+) pathway to restore and protect neurological function. By enhancing cellular energy production and utilization, CNM-Au8 plays a crucial role in maintaining neuronal health.
Mitochondrial dysfunction is a common cause of neuronal death in neurodegenerative diseases. CNM-Au8 aims to address this dysfunction, providing neuroprotection and promoting remyelination, potentially altering the course of these debilitating conditions. Extensive clinical trials have been conducted to evaluate the safety and efficacy of CNM-Au8, with over 650 years of cumulative subject exposure. The drug has demonstrated a strong safety profile with no serious adverse events linked to its use.
Clene is preparing for phase three programs for both ALS and MS. The company's innovative approach, supported by robust intellectual property and a global patient base of over 150, positions it as a leader in tackling neurodegenerative diseases. This development is significant as it offers new hope for patients suffering from these conditions and represents a major advancement in the field of neurological health.
For more information, visit www.Clene.com
